These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
830 related articles for article (PubMed ID: 17963263)
1. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263 [TBL] [Abstract][Full Text] [Related]
2. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727 [TBL] [Abstract][Full Text] [Related]
3. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921 [TBL] [Abstract][Full Text] [Related]
4. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder]. Asali MG; Kaneti J; Manor E Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439 [TBL] [Abstract][Full Text] [Related]
5. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. Bergman J; Reznichek RC; Rajfer J BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364 [TBL] [Abstract][Full Text] [Related]
6. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912 [TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510 [TBL] [Abstract][Full Text] [Related]
8. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T; Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414 [TBL] [Abstract][Full Text] [Related]
9. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520 [TBL] [Abstract][Full Text] [Related]
10. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive? Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL; Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938 [TBL] [Abstract][Full Text] [Related]
11. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562 [TBL] [Abstract][Full Text] [Related]
12. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Bubendorf L; Grilli B; Sauter G; Mihatsch MJ; Gasser TC; Dalquen P Am J Clin Pathol; 2001 Jul; 116(1):79-86. PubMed ID: 11447756 [TBL] [Abstract][Full Text] [Related]
13. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511 [TBL] [Abstract][Full Text] [Related]
14. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445 [TBL] [Abstract][Full Text] [Related]
15. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805 [TBL] [Abstract][Full Text] [Related]